Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer. Examples of a compound of formula (I) are: N-(2&rsquo,4&rsquo-difluoro-S-(S-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)biphenyl-3-yl)acetamide N-(3-(5-fluoropyridin-2-yl)-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]-imidazol-1-yl)phenyl)cyclopropanesulfonamide